Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: the Ultra-slow …
M Özkan, S Gündüz, OM Gürsoy, S Karakoyun… - American heart …, 2015 - Elsevier
Background Low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator
(t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis …
(t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis …
[引用][C] Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow …
M Özkan, S Gündüz, OM Gürsoy, S Karakoyun… - American Heart …, 2015 - cir.nii.ac.jp
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical
valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial | CiNii …
valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial | CiNii …
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow …
M Özkan, S Gündüz, OM Gürsoy, S Karakoyun… - American Heart …, 2015 - infona.pl
Low-dose (25mg), slow infusion (6hours) of tissue-type plasminogen activator (t-PA) with
repetition as needed has been shown to provide effective and safer thrombolysis in patients …
repetition as needed has been shown to provide effective and safer thrombolysis in patients …
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow …
M ÖZKAN, S GÜNDÜZ, O GÜRSOY… - AMERICAN HEART …, 2015 - avesis.ksbu.edu.tr
Background Low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator
(t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis …
(t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis …
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow …
M Özkan, S Gündüz, OM Gürsoy… - American Heart …, 2015 - europepmc.org
Background Low-dose (25mg), slow infusion (6hours) of tissue-type plasminogen activator (t-
PA) with repetition as needed has been shown to provide effective and safer thrombolysis in …
PA) with repetition as needed has been shown to provide effective and safer thrombolysis in …
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow …
M Özkan, S Gündüz, OM Gürsoy… - American heart …, 2015 - pubmed.ncbi.nlm.nih.gov
Background Low-dose (25mg), slow infusion (6hours) of tissue-type plasminogen activator (t-
PA) with repetition as needed has been shown to provide effective and safer thrombolysis in …
PA) with repetition as needed has been shown to provide effective and safer thrombolysis in …